INTRODUCTION
Ultraviolet light A (UVA) 1 (320-400 nm) comprises approximately 95% of the total solar UV (1) because all the ultraviolet C (UVC) (200-290 nm) and most of the ultraviolet B (UVB) (290-320 nm) radiation are absorbed by the earth's stratospheric ozone layer (2) . Currently UVA, like UVB, is considered to be a complete carcinogen (3) and to play an important role in the etiology of human skin cancer (4) . But, the activation of signaling molecules and their pathways implicated in the process following UVA irradiation (5, 6) are not well understood.
Therefore, the study of UVA-induced signal transduction will help in understanding the molecular mechanisms underlying UVA-induced carcinogenesis.
Activation of tumor cell proliferation requires an accelerated rate of protein synthesis, which is regulated in part by intracellular activation of several signaling protein kinase cascades that interact with the translational machinery of the ribosome (7) . Among them, S6 is a component of ribosomal proteins and is located at the interface between 40S and 60S ribosomal proteins (8) . Phosphorylation of S6 at multiple serine sites on its C-terminus was shown to be correlated with increased translation, especially of mRNAs containing a polypyrimidine tract in their 5' untranslated regions (5'TOP) (9) . This family of mRNAs constitutes as few as 100 to 200 genes, but makes up 20% to 30% of the total cellular mRNA, indicating that they are important for cell cycle progression. The family of serine/threonine kinases that mediate S6 phosphorylation are known as ribosomal S6 kinases, one of which is a 70-kDa S6 kinase (p70 S6K ) (8) . Accumulating evidence suggests that the prominent role of p70 S6K activation in mitogenesis may be to promote translation of mRNAs necessary for cell growth and division and to generate many of the molecules necessary for driving the cell cycle from G0/G1 to S phase (9) .
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Initially p70 S6K was isolated from mitogen-stimulated Swiss mouse 3T3 cells (10) .
Subsequently, two isoforms of p70 S6K (p70   S6K   /p85   S6K , collectively termed p70 S6K or S6K1) were found in purification, cloning, and expression studies (11) . Both isoforms are encoded by the same transcript with alternative translational start sites (12) . Based on evidence that an additional 23-amino acid extension at the N-terminus of p85 S6K was shown to function as a nuclear localization signal (NLS), p85 S6K appears to be exclusively nuclear, whereas p70 S6K is largely cytoplasmic (11, 12) . The p85 S6K may be responsible for phosphorylation of the free chromatin-bound nuclear form of S6 (13, 14) . Recently, deletion of the p70 S6K gene was shown to have no effect on S6 phosphorylation, 5'TOP mRNA translation, or the rate of cell growth, but resulted in a small mouse phenotype (15) . In p70 S6K -/-mice, another S6 kinase (S6K2) with a 70% overall amino acid homology with p70 S6K and a potential NLS at the C-terminus was found to partially compensate for loss of p70 S6K function (15) . Recently, another nuclear S6 kinaserelated kinase (SRK) was cloned and identified as a novel nuclear target of Akt (16) . Generally, the p70 S6K family plays a key role in the control of cell size, growth, and proliferation. Consistent with this concept, inhibition of p70 S6K activation by microinjection of neutralizing antibodies (17) or treatment of cells with rapamycin, an inhibitor of mammalian target of rapamycin (mTOR)-p70 S6K (18, 19, 20) , severely impeded cell cycle progression.
Although p70 S6K is known to be activated by various stimuli including growth factors, cytokines, 12-O-tetradecanoylphorbol-13-acetate (TPA), oncogenic products, Ca 2+ , and inhibitors of protein synthesis (5, 21) , the signal transduction pathway mediating p70 S6K is poorly
understood. An array of independently regulated protein kinases (12, 22, 23) are known to activate 70 S6K via phosphorylation of at least eight Ser/Thr sites in its three separate domains.
Thr229 in the p70 S6K activation loop within the catalytic domain has been shown to be 5 phosphorylated in vivo through the phosphatidylinositol-3 kinase (PI-3 kinase) pathway (24) and in vitro selectively by 3-phosphoinositide-dependent protein kinase 1 (PDK1) (25) . Thr229 phosphorylation has been shown to enable p70 S6K activity and be repressed by wortmannin, an inhibitor of PI-3 kinase (26) . Additionally, similar to Thr229, Ser371 located in the kinase extension domain, has been shown to influence p70 S6K activity and its phosphorylation is also regulated by the PI-3 kinase-dependent pathway (27) . Thr389 is another site for mitogenstimulated phosphorylation and is situated in a conserved 65-amino acid segment located immediately C-terminal to the catalytic domain (12, 22) . It plays an especially important role in p70 S6K activation because it influences both the phosphorylation of Thr229 in vitro by PDK1 and p70 S6K activity (22) . Although p70 S6K was shown to be phosphorylated by mTOR in vitro (28, 71) , a p70∆2-46/∆CT104 construct was shown to still be activated and phosphorylated at Thr389
in vivo in the presence of rapamycin, an mTOR inhibitor (12, 22, 29) . Other studies indicated that mTOR activity likely suppresses protein phosphatase 2A-mediated dephosphorylation of p70 S6K (30, 31, 32) .
At the same time that p70 S6K is activated by mitogens, the extracellular signal-regulated kinases (ERKs) pathway is also stimulated (23) , indicating that the activation of p70 S6K appears to coincide with that of ERKs. The proline-directed Ser/Thr (S/T-P) sites (Ser411, Ser418, and positive controls were subjected to SDS-PAGE and western immunoblotting with corresponding nonphosphorylated or phospho-specific antibodies according to the procedure as described above. 
PI-3 Kinase

Kinase Activity Assay for Protein Phosphatase 1-treated p70 S6K Preparations-
Deactivation of the p70 S6K preparations by protein phosphatase 1 (PP1) and reactivation by MAPKs were examined according to reported methods (72, 73) . Briefly, JB6 Cl 41 cells were starved for 36 h and then lysed in buffer A alone. The cell lysates were clarified by centrifugation at 17,000 g at 4 °C for 5 min and then supernatant fractions containing equal amounts of protein were subjected to immunoprecipitation with p70 S6K antibody as described above. The p70 S6K preparations were incubated at 30 °C for 30 min with 0.5 unit of PP1 or with no PP1 (as internal controls) in 100 µl buffer containing 50 mM Tris-HC1 (pH 7.0), 30 mM β-mercaptoethanl, 0.01% Brij-35 (Sigma). Then, PP1 activity was inhibited by the addition of NaF (10 mM). Deactivated p70 S6K preparations were saved by centrifugation and then incubated at (50 mU/µl), JNK2 (50 mU/µl), p38 kinase (10 ng/µl) (Upstate Biotechnology Inc.), and subsequent p70 S6K S6 kinase activity assay was performed as described above.
Statistical Analysis-Significant differences between the p70 S6K kinase activity after treatment and the corresponding control value were determined using the Student's t test.
RESULTS
UVA Induces Activation of p70 S6K in a Time-dependent Manner-Activation of p70
S6K was reported to occur through multi-site phosphorylations (12, 22, 23) . We investigated the effect of UVA on total p70 S6K kinase activity and found that UVA (160 kJ/m 2 ) stimulated p70 
UVA Induces Phosphorylation of p70
S6K -TPA and EGF are well-known tumor promoters that act during tumor promotion and progression (46, 47) and UVC is also an experimental carcinogen (48). TPA, EGF, and UVC were reported to induce p70 S6K phosphorylation (5, 30, 49, 50) and were therefore used as positive controls in this study. Our data showed that UVA (80 and 160 kJ/m 2 ) induced phosphorylation of p70 S6K at Ser411, Thr421/Ser424 and Thr389. The phosphorylation was at least equivalent to or greater than that induced by UVC (60 kJ/m 2 ), TPA (10 ng/ml), or EGF (100 ng/ml) (Fig. 1B) . (12) . Here, we assess the role of the PI-3 kinase pathway in UVAstimulated activation and phosphorylation of p70 S6K at Thr389, Ser411, and Thr421/Ser424. Our data showed that UVA-induced phosphorylation of p70 S6K at Thr389, but not at Ser411 or Thr421/Ser424, was inhibited by pretreatment of JB6 cells with wortmannin ( Fig. 3A) , a selective inhibitor of the PI-3 kinase p110 subunit (51). We also observed that wortmannin markedly suppressed activation of PI-3 kinase (Fig. 3B ) and p70 S6K ( Fig. 3C ; p<0.001) in response to UVA irradiation. Further, we used a JB6 cell line expressing a dominant negative mutant of PI-3 kinase p85 subunit (DNM-∆p85) (41) to study the role of the PI-3 kinase pathway in UVA-stimulated phosphorylation and activation of p70
UVA-induced Phosphorylation of p70
S6K
. As expected, PI-3 kinase activity induced by UVA was significantly lower in DNM-∆p85 cells (Fig. 3E) (12, 22, 28, 31, 32) . Our data showed that UVA-induced phosphorylation of p70 S6K at Thr389 was completely abrogated by pretreatment with rapamycin ( Fig. 4A) , a selective mTOR inhibitor that abolishes mTOR function both in vivo and in vitro (12, 53) . UVA-induced phosphorylation of p70 S6K at Ser411 and Thr421/Ser424 also was partially blocked by rapamycin pretreatment (Fig. 4A) . Furthermore, our data demonstrated that p70 S6K kinase activation by exposure to UVA irradiation was significantly (p<0.01) suppressed by rapamycin pretreatment (Fig. 4B) . These results suggest that mTOR may preferentially mediate p70 S6K phosphorylation at Thr389 leading to its activation.
PD98059 and DNM-ERK2 Inhibit UVA-induced Activation and Phosphorylation of p70
S6K at All Four Sites-ERKs were reported to phosphorylate p70 S6K in vitro (33) , but later reports indicated that p70 S6K activation was independent of the Ras/MAPK pathway (34, 35) .
However, more recently, ERKs were shown to be required for activation of p70 S6K in vivo (22, 23) . In our present experiments, we used PD98059, an inhibitor of MEK1 (50, 54) to determine the role of ERKs in activation and phosphorylation of p70 S6K at Thr389, Ser411, and Thr421/Ser424. Our data showed that pretreatment of JB6 Cl 41 cells with PD98059 markedly blocked UVA-induced ERKs phosphorylation, p70 S6K phosphorylation at Thr421/Ser424 and Thr389, and partially inhibited phosphorylation of p70 S6K at Ser411 (Fig. 5A) . Further, UVAstimulated p70 S6K kinase activity was also significantly suppressed (p<0.001) by PD98059 pretreatment (Fig. 5C ). However, Kamakura et al. (55) reported that PD98059 inhibits EGFinduced ERK5 activation. Therefore, to further study the role of ERKs in the phosphorylation and activation of p70
S6K
, we used a JB6 cell line stably expressing the protein of a dominant negative mutant of ERK2 (DNM-ERK2) (39) . As expected, UVA-induced phosphorylation and activation of ERKs were blocked by DNM-ERK2 ( Fig. 5B and data not shown). Our data also showed that following UVA irradiation p70 S6K phosphorylation at Thr421/Ser424 and Thr389 was almost completely blocked and the phosphorylation at Ser411 was partially inhibited in DNM-ERK2 cells compared to control Cl 41 cells (Fig. 5B) . Moreover, p70 S6K kinase activity induced by UVA was significantly (p<0.001) abrogated in DNM-ERK2 cells compared to control cells (Fig. 5D ). On the other hand, PD98059 pretreatment ( Fig. 5A ) and DMN-ERK2 expression ( Fig. 5B ) had no effect on UVA-induced p38 kinase phosphorylation. Thus, these results suggest that ERKs may be involved in p70 S6K activation and phosphorylation at Thr421/Ser424, Thr389 and Ser411 in JB6 cells exposed to UVA irradiation.
SB202190 and DNM-p38 inhibit UVA-induced p70 S6K Activation and Phosphorylation at
Thr389 but not Ser411 or Thr421/Ser424-To determine whether p38 kinase has an effect on activation and phosphorylation of p70
S6K
, we employed SB202190, a selective inhibitor of p38 kinase (56) . Our data showed that pretreatment of JB6 cells with SB202190 prevented phosphorylation of p38 kinase and p70 S6K at Thr389, but had no effect on ERKs and p70 S6K phosphorylation at Ser411 or Thr421/Ser424 following UVA irradiation (Fig. 6A) . We observed that SB202190 pretreatment also significantly (p<0.01) suppressed p70 S6K activation after cells by guest on http://www.jbc.org/ Downloaded from were exposed to UVA irradiation (Fig. 6C) . To further investigate the role of p38 kinase in UVA-stimulated activation and phosphorylation of p70
, we used a JB6 cell line expressing a dominant negative mutant of p38 kinase (DNM-p38) (40) . As expected, DNM-p38 selectively inhibited phosphorylation and activation of p38 kinase, but not ERKs, in response to UVA (Fig.   6B and data not shown). Furthermore, DNM-p38 only blocked Thr389 phosphorylation, but had no effect on phosphorylation of p70 S6K at Ser411 or Thr421/Ser424, compared to corresponding control Cl 41 cells (Fig. 6B) . In addition, UVA-stimulated p70 S6K kinase activity was suppressed (p<0.05) in DNM-p38 cells compared to control Cl 41 cells (Fig. 6D) . Therefore, these results indicated that p38 kinase may be implicated in UVA-induced activation and phosphorylation of p70 S6K at Thr389, but not at Ser411 or Thr421/424.
JNKs May be Involved in UVA-induced Activation and Phosphorylation of p70 S6K at
Thr389 and Ser411 but not at Thr421/Ser424-We found that UVA-stimulated activation of p70 S6K was significantly abolished by pretreatment of JB6 cells with PD169316 (Fig. 6C) , a novel inhibitor of p38 kinase and JNKs (57, 58) , suggesting that JNKs, like ERKs and p38 kinase, may be implicated in UVA-induced activation and phosphorylation of p70
S6K
. Further, we used cell lines with a dominant negative JNK1 mutant (DNM-JNK1) (38) and embryo Jnk1-/-and Jnk2-/-knockout cells to assess whether JNKs play a role in activation and phosphorylation of p70 S6K induced by UVA. Our data showed that UVA-induced phosphorylation of p70 S6K at Ser411 and Thr389, but not at Thr421/Ser424, was inhibited by DNM-JNK1 compared to control Cl 41 cells (Fig. 7A) , and the phosphorylation at the same two sites was attenuated in Jnk1-/-and Jnk2-/-knockout cells compared to wild-type Jnk+/+ cells (Fig. 7B) . Also, p70 S6K activation by UVA was partially inhibited (p<0.05) in DNM-JNK1 cells (Fig. 7C ) and almost totally blocked (p<0.001) in Jnk1-/-and Jnk2-/-cells (Fig. 7D) proteins are activated by incubation with active MAPKs in vitro (Fig. 8B) , whereas, the S6 peptide, a substrate of p70
, is not phosphorylated by active MAPKs in vitro (Fig. 8C) . These results suggest that the p70 S6K proteins may co-immunoprecipitate with other kinases that can phosphorylate the S6 peptide, or with additional p70 S6K activating kinases such as PDK1. Our studies showed further that in the UVA-treated cells, the p70 S6K proteins co-immunoprecipitated strongly with PI-3 kinase (Fig. 8D ), very weakly with PDK1 (Fig. 8E ), but not with Akt ( Fig.   8F ), as compared with corresponding controls. MAPK downstream kinases, including RSK1, RSK2, RSK3, or MSK1, can also phosphorylate the S6 peptide. However, the p70
immunoprecipitates were not contaminated with any phosphorylated or nonphosphorylated
MAPK downstream kinases (data not shown). In addition, immunoprecipitates from normal non-immune serum did not contain any of the above-mentioned kinases (data not shown).
Therefore, our results suggest that the activation and phosphorylation of p70 S6K may be mediated by MAPKs in cooperation with PI-3 kinase and possibly PDK1 or an additional unidentified p70 S6K -activating kinase.
Partial Reactivation of PP1-treated p70 S6K Preparations by ERKs-PP1-treated p70
S6K
preparations were employed here to determine whether the IP-p70 S6K used above was partially phosphorylated at non-MAPKs sites and, thus, be "primed" for its phosphorylation and activation by MAPKs in vitro. Our data showed the S6 kinase activity decreased by about 40%
following treatment of the IP-p70 S6K with PP1 compared to that with no PP1 treatment (Fig. 9A 
DISCUSSION
Activation of p70 S6K is known to occur though a hierarchical multi-site phosphorylation process directed at three separate domains: 1) a cluster of S/T-P sites (Ser411, Ser418, Thr421, Ser424) in an autoinhibitory domain in the noncatalytic C-terminal tail; 2) Thr229 in the activation loop of the catalytic domain; and 3) Thr389 and another two S/T-P sites (Ser371 and possibly Thr367) in the kinase extension domain immediately C-terminal to the catalytic domain (12, 22) . Here, we employed phospho-specific anti-peptide antibodies to determine the changes in phosphorylation of p70 S6K at Thr389, Ser411, and Thr421/Ser424 in response to UVA exposure. We found that exposure of JB6 cells to UVA irradiation stimulated p70 S6K kinase activity in a time-dependent manner and simultaneously induced a dose-and time-dependent phosphorylation of p70 S6K at the four sites, suggesting that phosphorylation at these sites may indirectly reflect p70 S6K kinase activity. However, upstream kinase pathways leading to phosphorylation and activation of p70 S6K are not well understood (12, 22, 25 Activation of the PI-3 kinase pathways was reported to be required for phosphorylation and activation of p70 S6K (12 ,23, 59 ). PDK1, a downstream kinase of PI-3 kinase, was clearly shown to be a markedly selective kinase for Thr229 phosphorylation contributing to p70 S6K activation (12, 22, 25, 60) . In addition, Thr389 phosphorylation was also shown to be mediated by PI-3 kinase/PDK1 and contributed to the activation of p70 S6K (12, 22, 60) . More recent studies indicated that Thr389 phosphorylation might create a PDK1 docking site in p70 S6K that recruits and activates PDK1 leading to Thr229 phosphorylation and its activation (61) . These previous studies suggest that phosphorylation at Th229 and Thr389 occurs through the PI-3 kinase pathway and reflects p70 S6K activation in vivo. We observed that the changes in Thr389 phosphorylation correlate with those of p70 S6K kinase activity when JB6 cells were exposed to UVA irradiation. Moreover, UVA-stimulated p70 S6K activity and phosphorylation of Thr389, but not Ser411 or Thr421/Ser424, were prevented by wortmannin, a selective inhibitor of the PI-3 kinase p110 subunit, and also were abolished by a dominant negative mutant of the PI-3 kinase p85 subunit (DNM-∆p85), further suggesting that UVA-stimulated activation and phosphorylation at Thr389 may be regulated by the PI-3 kinase pathway but that the phosphorylation at the autoinhibitory domain S/T-P sites (Ser411, and Thr421/Ser424) occurs through PI-3 kinase independent pathways.
However, a kinase specific for Thr389 phosphorylation regulated by PI-3 kinase has not so far been identified. mTOR was shown to be a critical kinase in regulation of p70 S6K activation.
Immunoprecipitation studies showed that p70 S6K at Thr389 was phosphorylated in vitro by mTOR (28, 71) . But, other studies showed that regulation of p70 S6K activation and Thr389 phosphorylation by mTOR occurs through inhibition of protein phosphatase 2A (PP2A)-mediated dephosphorylation (12, 22, 29, 31, 32) . Here, UVA-stimulated p70 S6K activity and phosphorylation at Thr389 were completely abrogated by rapamycin, an mTOR inhibitor (20, 53) , suggesting that mTOR is also required for p70 S6K activation and phosphorylation at Thr389 induced by UVA exposure. On the other hand, UVA-induced phosphorylation at Ser411 and Thr421/Ser424 of p70 S6K were only partially blocked by rapamycin. These data suggest that inhibition of phosphorylation of p70 S6K at the four sites leading to its inactivation may occur via rapamycin-induced PP2A activation (12, 30, 51) , inasmuch as insulin-induced inhibition of PP2A activity is blocked by rapamycin (62), and these rapamycin-sensitive S/T-P sites in the autoinhibitory domain do not serve as a substrate for mTOR in vitro (28) . However, the sites in eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) phosphorylated by mTOR all contain an S/T-P motif (12) , characteristic of sites phosphorylated by proline-directed kinases (e.g., MAPK). Therefore, mTOR might phosphorylate similar S/T-P motifs on p70 S6K in the presence of an unidentified cofactor in vivo.
Although the role of MAPKs in the activation of the p70 S6K signaling pathway has been controversial (12), phosphorylation of Thr229 by PDK1 and of Thr389 by mTOR in vitro results in only partial activation of p70 S6K (12, 22, 25, 28) (30) . However, our studies suggest that p38 kinase may also be required for UVAstimulated p70 S6K activation and phosphorylation at Thr389, inasmuch as UVA-stimulated p70 S6K activation and phosphorylation at Thr389 were blocked by a p38 kinase inhibitor, SB202190, and also inhibited by a dominant negative mutant of p38 kinase (DNM-p38). On the other hand, SB202190 and DNM-p38 had no effect on UVA-induced phosphorylation at Ser411 or Thr421/Ser424. These results suggest that prior phosphorylation of p70 S6K at S/T-P sites other than Ser411 and Thr421/Ser424 in the autoinhibitory domain may occur via activation of p38 kinase and facilitate a second phosphorylation at Thr389 and subsequent activation of p70
S6K
.
But another possibility that cannot be ruled out is that p38 kinase may be an activator of Akt Indeed, phosphorylation at the S/T-P sites in the autoinhibitory domain is confirmed to participate in phosphorylation of the p70 S6K activation loop leading to its activation (25, 64, 65, 69) . Additionally, we found that the p70 S6K proteins precipitated with PI-3 kinase and possibly PDK1, but not with Akt or MAPK downstream kinases including RSK1, RSK2, RSK3, and MSK1 ( Fig. 8 and data not shown) . Furthermore, our data showed that the p70 S6K complex possessed a partial basal level of phosphorylation and, thus, was "primed" for its activation by
MAPKs in vitro, although p70 S6K activity was shown not to be induced by MAPKs alone in vitro (12, 22, 23, 28, 59) . In fact, active PI-3 kinase (p110) has been shown to induce p70 S6K activation and phosphorylation at Thr229, Thr389, Ser411, and Thr421/Ser424 in vivo (22) .
Also, p70 S6K forms a complex with PDK1 in co-transfected cells (70) , but the binding site has not been identified. Recently, Gu et al. (74) reported that interrelationships between ERKs and p70 S6K were characterized and a complex between both kinases was documented by immunoprecipitation, suggesting that p70 S6K may be a potential substrate of ERKs or be dependent upon ERKs. This idea was supported by our experiments showing that PP1-deactivated p70 S6K preparations were partially reactivated by ERKs in vitro, but the possibility of the existance of an unidentified kinase or a coactivator in our reaction system cannot be ruled out. Thus, these results suggest that full activation of p70 S6K may be induced by cooperation of MAPKs with PI-3 kinase/PDK1 or an unidentified p70 S6K -activating kinase. Another possibility remaining to be determined is that prior autoinhibitory domain phosphorylation by MAPKs may induce a conformational change in p70 S6K that allows for a second phosphorylation at the S/T-P sites (Ser371 and possibly Thr367) in the kinase extension domain by MAPKs contributing to p70 S6K activation (22, 26, 27 
